S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:ORTX - Orchard Therapeutics Stock Price, Forecast & News

$12.04
-0.37 (-2.98 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$11.78
Now: $12.04
$12.24
50-Day Range
$12.04
MA: $13.34
$15.71
52-Week Range
$9.78
Now: $12.04
$21.64
Volume190,999 shs
Average Volume276,547 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.98
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORTX
CUSIPN/A
CIKN/A
Phone44-20-3384-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.08 million
Book Value$3.63 per share

Profitability

Miscellaneous

Employees180
Market Cap$1.16 billion
Next Earnings Date2/27/2020 (Confirmed)
OptionableNot Optionable

Receive ORTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ORTX and its competitors with MarketBeat's FREE daily newsletter.


Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics PLC - (NASDAQ:ORTX) issued its earnings results on Wednesday, November, 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.05. The firm earned $1.92 million during the quarter, compared to the consensus estimate of $0.53 million. View Orchard Therapeutics' Earnings History.

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Orchard Therapeutics.

How can I listen to Orchard Therapeutics' earnings call?

Orchard Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for ORTX?

5 equities research analysts have issued 12 month price objectives for Orchard Therapeutics' stock. Their forecasts range from $21.00 to $31.00. On average, they anticipate Orchard Therapeutics' stock price to reach $26.20 in the next year. This suggests a possible upside of 117.6% from the stock's current price. View Analyst Price Targets for Orchard Therapeutics.

What is the consensus analysts' recommendation for Orchard Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orchard Therapeutics.

Has Orchard Therapeutics been receiving favorable news coverage?

News coverage about ORTX stock has trended somewhat positive on Monday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Orchard Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Orchard Therapeutics.

Are investors shorting Orchard Therapeutics?

Orchard Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totalling 840,300 shares, an increase of 69.0% from the December 31st total of 497,200 shares. Based on an average trading volume of 271,100 shares, the short-interest ratio is presently 3.1 days. Approximately 1.2% of the company's shares are sold short. View Orchard Therapeutics' Current Options Chain.

Who are some of Orchard Therapeutics' key competitors?

What other stocks do shareholders of Orchard Therapeutics own?

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the folowing people:
  • Mr. Mark A. Rothera, CEO, Pres & Director (Age 56)
  • Dr. Anne Dupraz-Poiseau, Chief Regulatory Officer
  • Mr. Frank E. Thomas, CFO & Chief Bus. Officer (Age 49)
  • Ms. Ran Zheng, Chief Technical Officer
  • Prof. Bobby Gaspar Ph.D., M.D., Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 54)

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (12.76%), RA Capital Management L.P. (6.64%), Baillie Gifford & Co. (2.85%), Artisan Partners Limited Partnership (2.80%), Driehaus Capital Management LLC (1.53%) and ArrowMark Colorado Holdings LLC (1.36%). View Institutional Ownership Trends for Orchard Therapeutics.

Which major investors are selling Orchard Therapeutics stock?

ORTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Barclays PLC, Bank of America Corp DE and Victory Capital Management Inc.. View Insider Buying and Selling for Orchard Therapeutics.

Which major investors are buying Orchard Therapeutics stock?

ORTX stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., RA Capital Management L.P., Artisan Partners Limited Partnership, Casdin Capital LLC, ArrowMark Colorado Holdings LLC, New York State Common Retirement Fund, Marshall Wace LLP and Berylson Capital Partners LLC. View Insider Buying and Selling for Orchard Therapeutics.

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $12.04.

How big of a company is Orchard Therapeutics?

Orchard Therapeutics has a market capitalization of $1.16 billion and generates $2.08 million in revenue each year. The company earns $-230,490,000.00 in net income (profit) each year or ($10.22) on an earnings per share basis. Orchard Therapeutics employs 180 workers across the globe.View Additional Information About Orchard Therapeutics.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is http://www.orchard-tx.com/.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 44-20-3384-6700.


MarketBeat Community Rating for Orchard Therapeutics (NASDAQ ORTX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  278
MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote "Outperform" if you believe ORTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel